Pediatric Nephrology

, Volume 25, Issue 4, pp 591–601 | Cite as

Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism

  • Jyothsna Gattineni
  • Michel BaumEmail author


There are a number of hypophosphatemic disorders due to renal phosphate wasting that cannot be explained by elevated levels of parathyroid hormone. The circulating factors responsible for the phosphaturia have been designated as phosphatonins. Studies of patients with tumor-induced osteomalacia and other genetic diseases of phosphate metabolism have resulted in the identification of a number of hormones that regulate phosphate homeostasis, including matrix extracellular phosphoglycoprotein (MEPE), secreted frizzled-related protein 4 (sFRP-4), dentin matrix protein 1 (DMP1), fibroblast growth factor 7 (FGF7), fibroblast growth factor 23 (FGF23), and Klotho. Our understanding of the actions of these hypophosphatemic peptides has been enhanced by studies in mice either overexpressing or not expressing these hormones. This review focuses on FGF23 since its regulation is disordered in diseases that affect children, such as X-linked hypophosphatemia, autosomal dominant and recessive hypophosphatemic rickets as well as chronic kidney disease. Recent studies have shown that FGF23 is unique among the FGFs in its requirement for Klotho for receptor activation. Here, we also discuss new potentially clinically important data pointing to the receptor(s) that mediate the binding and action of FGF23 and Klotho.


Hypophosphatemia Klotho Proximal tubule Sodium phosphate cotransporter 



This work was supported by NIH grants DK41612, DK065842, and DK078596 to M.B, T32 DK07257 (Peter Igarashi and M.B.), and the O’Brien Center P30DK079328 (Peter Igarashi, PI).


  1. 1.
    Forster IC, Hernando N, Biber J, Murer H (2006) Proximal tubular handling of phosphate: A molecular perspective. Kidney Int 70:1548–1559PubMedGoogle Scholar
  2. 2.
    Levi M, Lotscher M, Sorribas V, Custer M, Arar M, Kaissling B, Murer H, Biber J (1994) Cellular mechanisms of acute and chronic adaptation of rat renal P(I) transporter to alterations in dietary P(I). Am J Physiol 267:F900–F908PubMedGoogle Scholar
  3. 3.
    Murer H, Forster I, Hernando N, Lambert G, Traebert M, Biber J (1999) Posttranscriptional regulation of the proximal tubule NaPi-II transporter in response to PTH and dietary P(I). Am J Physiol 277:F676–F684PubMedGoogle Scholar
  4. 4.
    Segawa H, Kaneko I, Takahashi A, Kuwahata M, Ito M, Ohkido I, Tatsumi S, Miyamoto K (2002) Growth-related renal type II Na/Pi cotransporter. J Biol Chem 277:19665–19672PubMedGoogle Scholar
  5. 5.
    Segawa H, Yamanaka S, Ito M, Kuwahata M, Shono M, Yamamoto T, Miyamoto K (2005) Internalization of renal type IIc Na-Pi cotransporter in response to a high-phosphate diet. Am J Physiol Renal Physiol 288:F587–F596PubMedGoogle Scholar
  6. 6.
    Hernando N, Forgo J, Biber J, Murer H (2000) PTH-Induced downregulation of the type IIa Na/P(i)-cotransporter is independent of known endocytic motifs. J Am Soc Nephrol 11:1961–1968PubMedGoogle Scholar
  7. 7.
    Yang LE, Maunsbach AB, Leong PK, McDonough AA (2004) Differential traffic of proximal tubule Na + transporters during hypertension or PTH: NHE3 to base of microvilli vs. NaPi2 to endosomes. Am J Physiol Renal Physiol 287:F896–F906PubMedGoogle Scholar
  8. 8.
    Zhang Y, Norian JM, Magyar CE, Holstein-Rathlou NH, Mircheff AK, McDonough AA (1999) In vivo PTH provokes apical NHE3 and NaPi2 redistribution and Na-K-ATPase inhibition. Am J Physiol 276:F711–F719PubMedGoogle Scholar
  9. 9.
    Takahashi F, Morita K, Katai K, Segawa H, Fujioka A, Kouda T, Tatsumi S, Nii T, Taketani Y, Haga H, Hisano S, Fukui Y, Miyamoto KI, Takeda E (1998) Effects of dietary Pi on the renal Na + -dependent Pi transporter NaPi-2 in thyroparathyroidectomized rats. Biochem J 333:175–181PubMedGoogle Scholar
  10. 10.
    Keusch I, Traebert M, Lotscher M, Kaissling B, Murer H, Biber J (1998) Parathyroid hormone and dietary phosphate provoke a lysosomal routing of the proximal tubular Na/Pi-cotransporter type II. Kidney Int 54:1224–1232PubMedGoogle Scholar
  11. 11.
    Segawa H, Yamanaka S, Onitsuka A, Tomoe Y, Kuwahata M, Ito M, Taketani Y, Miyamoto K (2007) Parathyroid hormone-dependent endocytosis of renal type IIc Na-Pi cotransporter. Am J Physiol Renal Physiol 292:F395–F403PubMedGoogle Scholar
  12. 12.
    Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R (2005) Fibroblast growth factor 7: An inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90:1012–1020PubMedGoogle Scholar
  13. 13.
    de Beur SMJ, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC (2002) Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:1102–1110PubMedGoogle Scholar
  14. 14.
    Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan de Beur SM, Schiavi SC, Kumar R (2003) Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785–794PubMedGoogle Scholar
  15. 15.
    Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky E, Brown AJ (2006) FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 104:23–32Google Scholar
  16. 16.
    Dobbie H, Unwin RJ, Faria NJR, Shirley DG (2008) Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant 23:730–733PubMedGoogle Scholar
  17. 17.
    Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, Tayback M, Fisher LW (2004) Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 89:4158–4161PubMedGoogle Scholar
  18. 18.
    Bresler D, Bruder J, Mohnike K, Fraser WD, Rowe PS (2004) Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 183:R1–R9PubMedGoogle Scholar
  19. 19.
    Feng JQ, Ward LM, Liu SG, Lu YB, Xie YX, Yuan BZ, Yu XJ, Rauch F, Davis SI, Zhang SB, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310–1315PubMedGoogle Scholar
  20. 20.
    Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500–6505PubMedGoogle Scholar
  21. 21.
    Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179–3182PubMedGoogle Scholar
  22. 22.
    Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB (2004) Transgenic mice expressing Fibroblast Growth Factor 23 under the control of the {alpha}1(I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis. Endocrinology 145:3087–3094PubMedGoogle Scholar
  23. 23.
    Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2004) FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314:409–414PubMedGoogle Scholar
  24. 24.
    Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435PubMedGoogle Scholar
  25. 25.
    Perwad F, Zhang MY, Tenenhouse HS, Portale AA (2007) Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 293:F1577–F1583PubMedGoogle Scholar
  26. 26.
    Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, Baum M (2009) FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol. doi: 10.1152/ajprenal.90742.2008 PubMedGoogle Scholar
  27. 27.
    Ben Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003–4008PubMedGoogle Scholar
  28. 28.
    Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T (2005) Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289:F1088–F1095PubMedGoogle Scholar
  29. 29.
    Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509–1518PubMedGoogle Scholar
  30. 30.
    Shimada T, Kakitani M, Hasegawa H, Yamazaki Y, Ohguma A, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T (2002) Targeted ablation of FGF-23 causes hyperphosphatemia, increased 1, 25-dihydroxyvitamin D level and severe growth retardation. J Bone Miner Res 17:S168Google Scholar
  31. 31.
    Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD (2007) Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18:2116–2124PubMedGoogle Scholar
  32. 32.
    Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG (2007) Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 26:75–84PubMedGoogle Scholar
  33. 33.
    Razzaque MS, Sitara D, Taguchi T, St Arnaud R, Lanske B (2006) Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20:720–722PubMedGoogle Scholar
  34. 34.
    Sitara D, Razzaque MS, St Arnaud R, Huang W, Taguchi T, Erben RG, Lanske B (2006) Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 169:2161–2170PubMedGoogle Scholar
  35. 35.
    Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC (2001) FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284:977–981PubMedGoogle Scholar
  36. 36.
    Yamashita T, Konishi M, Miyake A, Inui K, Itoh N (2002) Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277:28265–28270PubMedGoogle Scholar
  37. 37.
    Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407:1029–1034PubMedGoogle Scholar
  38. 38.
    Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R (2003) Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc Natl Acad Sci USA 100:2357–2362PubMedGoogle Scholar
  39. 39.
    Yamashita T, Hasegawa H, Yamazaki Y, Kawata T, Urakawa I, Shimada T, Takeuchi Y, Fujita T, Fukumoto S, Nagano N (2002) Involvement of FGF-23 in abnormal vitamin D and mineral metabolism associated with renal insufficiency. J Am Soc Nephrol 13:577AGoogle Scholar
  40. 40.
    Baum M, Schiavi S, Dwarakanath V, Quigley R (2005) Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules 2. Kidney Int 68:1148–1153PubMedGoogle Scholar
  41. 41.
    Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18:2683–2688PubMedGoogle Scholar
  42. 42.
    Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305–1315PubMedGoogle Scholar
  43. 43.
    Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N (2005) Circulating FGF-23 is regulated by 1{alpha}, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–2549PubMedGoogle Scholar
  44. 44.
    Yu X, Sabbagh Y, Davis SI, Demay MB, White KE (2005) Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating FGF23 concentrations. Bone 36:971–977PubMedGoogle Scholar
  45. 45.
    Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto K (2005) Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288:E1101–E1109PubMedGoogle Scholar
  46. 46.
    Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA (2005) Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146:5358–5364PubMedGoogle Scholar
  47. 47.
    Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS (2006) Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21:1187–1196PubMedGoogle Scholar
  48. 48.
    Ferrari SL, Bonjour JP, Rizzoli R (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519–1524PubMedGoogle Scholar
  49. 49.
    Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B (2004) Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421–432PubMedGoogle Scholar
  50. 50.
    Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45–51PubMedGoogle Scholar
  51. 51.
    Segawa H, Yamanaka S, Ohno Y, Onitsuka A, Shiozawa K, Aranami F, Furutani J, Tomoe Y, Ito M, Kuwahata M, Imura A, Nabeshima Y, Miyamoto K (2007) Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 292:F769–F779PubMedGoogle Scholar
  52. 52.
    Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774PubMedGoogle Scholar
  53. 53.
    Bai X, Dinghong Q, Miao D, Goltzman D, Karaplis AC (2009) Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype. Am J Physiol Endocrinol Metab 296:E79–E88PubMedGoogle Scholar
  54. 54.
    Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, Goetz R, Mohammadi M, Lanske B, Razzaque MS (2009) In vivo genetic evidence for Klotho-dependent, fibroblast growth factor 23 (FGF23)-mediated regulation of systemic phosphate homeostasis. FASEB J 23:433–441PubMedGoogle Scholar
  55. 55.
    Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K (2004) Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 29:91–99PubMedGoogle Scholar
  56. 56.
    Hu MC, Zhang J, Rosenblatt KP, Baum M, Kuro-o M, Moe O (2006) Klotho inhibition of Na-phosphate transporter (Na/Pi2a) in OK cells. J Am Soc Nephrol 17:354A–355AGoogle Scholar
  57. 57.
    Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139–149PubMedGoogle Scholar
  58. 58.
    Itoh N, Ornitz DM (2004) Evolution of the Fgf and Fgfr gene families. Trends Genet 20:563–569PubMedGoogle Scholar
  59. 59.
    Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120–6123PubMedGoogle Scholar
  60. 60.
    Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD (2008) FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 19:2342–2350PubMedGoogle Scholar
  61. 61.
    Yamashita T, Yoshioka M, Itoh N (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494–498PubMedGoogle Scholar
  62. 62.
    Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM (2004) FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455–462PubMedGoogle Scholar
  63. 63.
    The ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348Google Scholar
  64. 64.
    Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419–37426PubMedGoogle Scholar
  65. 65.
    Mirams M, Robinson BG, Mason RS, Nelson AE (2004) Bone as a source of FGF23: regulation by phosphate? Bone 35:1192–1199PubMedGoogle Scholar
  66. 66.
    Bianchine JW, Stambler AA, Harrison HE (1971) Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Arctic Ser 7:287–295Google Scholar
  67. 67.
    Bai XY, Miao D, Goltzman D, Karaplis AC (2003) The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843–9849PubMedGoogle Scholar
  68. 68.
    White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086PubMedGoogle Scholar
  69. 69.
    Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674–681PubMedGoogle Scholar
  70. 70.
    Econs MJ, McEnery PT, Lennon F, Speer MC (1997) Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 100:2653–2657PubMedGoogle Scholar
  71. 71.
    Imel EA, Hui SL, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520–526PubMedGoogle Scholar
  72. 72.
    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663PubMedGoogle Scholar
  73. 73.
    Econs MJ, Drezner MK (1994) Tumor-induced osteomalacia–unveiling a new hormone. N Engl J Med 330:1679–1681PubMedGoogle Scholar
  74. 74.
    Cai Q, Hodgson SF, Kao PC, Lennon VA, Klee GG, Zinsmiester AR, Kumar R (1994) Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 330:1645–1649PubMedGoogle Scholar
  75. 75.
    White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H, Econs MJ (2001) The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endorinol Metab 86:497–500Google Scholar
  76. 76.
    Gore MO, Welch BJ, Geng W, Kabbani W, Maalouf NM, Zerwekh JE, Moe OW, Sakhaee K (2008) Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis. Kidney Int. doi: 10.1038/ki.2008.355 PubMedGoogle Scholar
  77. 77.
    Chalew SA, Lovchik JC, Brown CM, Sun CC (1996) Hypophosphatemia induced in mice by transplantation of a tumor-derived cell line from a patient with oncogenic rickets. J Pediatr Endocrinol Metab 9:593–597PubMedGoogle Scholar
  78. 78.
    Toyosawa S, Tomita Y, Kishino M, Hashimoto J, Ueda T, Tsujimura T, Aozasa K, Ijuhin N, Komori T (2004) Expression of dentin matrix protein 1 in tumors causing oncogenic osteomalacia. Mod Pathol 17:573–578PubMedGoogle Scholar
  79. 79.
    Rowe PSN, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL (2000) MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54–68PubMedGoogle Scholar
  80. 80.
    Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, de Beur SMJ, Schiavi SC, Kumar R (2003) Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785–794PubMedGoogle Scholar
  81. 81.
    Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O’Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1–30PubMedGoogle Scholar
  82. 82.
    Jan de Beur SM (2005) Tumor-induced osteomalacia. JAMA 294:1260–1267PubMedGoogle Scholar
  83. 83.
    Perry W, Stamp TC (1978) Hereditary hypophosphataemic rickets with autosomal recessive inheritance and severe osteosclerosis. A report of two cases. J Bone Joint Surg Br 60-B:430–434PubMedGoogle Scholar
  84. 84.
    Scriver CR, Reade T, Halal F, Costa T, Cole DE (1981) Autosomal hypophosphataemic bone disease responds to 1,25-(OH)2D3. Arch Dis Child 56:203–207PubMedGoogle Scholar
  85. 85.
    Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Juppner H, Strom TM (2006) DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248–1250PubMedGoogle Scholar
  86. 86.
    Almushayt A, Narayanan K, Zaki AE, George A (2006) Dentin matrix protein 1 induces cytodifferentiation of dental pulp stem cells into odontoblasts. Gene Ther 13:611–620PubMedGoogle Scholar
  87. 87.
    Narayanan K, Ramachandran A, Hao J, He G, Park KW, Cho M, George A (2003) Dual functional roles of dentin matrix protein 1. Implications in biomineralization and gene transcription by activation of intracellular Ca2+ store. J Biol Chem 278:17500–17508PubMedGoogle Scholar
  88. 88.
    Imel EA, Econs MJ (2007) Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23. Pediatr Endocrinol Rev 4[Suppl 4]:434–439PubMedGoogle Scholar
  89. 89.
    Weinstein LS, Yu S, Warner DR, Liu J (2001) Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 22:675–705PubMedGoogle Scholar
  90. 90.
    Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688–1695PubMedGoogle Scholar
  91. 91.
    Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Robey PG (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683–692PubMedGoogle Scholar
  92. 92.
    Schwindinger WF, Francomano CA, Levine MA (1992) Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 89:5152–5156PubMedGoogle Scholar
  93. 93.
    Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, Van Wyk JJ, Merino MJ, Feuillan PP, Spiegel AM (1993) Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 123:509–518PubMedGoogle Scholar
  94. 94.
    Tenenhouse HS, Econs MJ (2001) Mendelian hypophosphatemias. In: Scriver CR, Beaudet AL, Sly WS, Valley D (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 5039–5067Google Scholar
  95. 95.
    Scriver CR, Reade TM, DeLuca HF, Hamstra AJ (1978) Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med 299:976–979PubMedGoogle Scholar
  96. 96.
    Drezner MK, Lyles KW, Haussler MR, Harrelson JM (1980) Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia. J Clin Invest 66:1020–1032PubMedGoogle Scholar
  97. 97.
    Fukase M, Avioli LV, Birge SJ, Chase LR (1984) Abnormal regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase activity by calcium and calcitonin in renal cortex from hypophosphatemic (Hyp) mice. Endocrinology 114:1203–1207PubMedGoogle Scholar
  98. 98.
    Tenenhouse HS, Jones G (1990) Abnormal regulation of renal vitamin D catabolism by dietary phosphate in murine X-linked hypophosphatemic rickets. J Clin Invest 85:1450–1455PubMedGoogle Scholar
  99. 99.
    Holm IA, Huang X, Kunkel LM (1997) Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet 60:790–797PubMedGoogle Scholar
  100. 100.
    The HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130–136Google Scholar
  101. 101.
    Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS (1997) Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99:1200–1209PubMedGoogle Scholar
  102. 102.
    Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960PubMedGoogle Scholar
  103. 103.
    Weber TJ, Liu SG, Indridason OS, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227–1234PubMedGoogle Scholar
  104. 104.
    Guo R, Liu S, Spurney RF, Quarles LD (2001) Analysis of recombinant Phex: an endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab 281:E837–E847PubMedGoogle Scholar
  105. 105.
    Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ (2007) A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117:2684–2691PubMedGoogle Scholar
  106. 106.
    Lyles KW, Burkes EJ, Ellis GJ, Lucas KJ, Dolan EA, Drezner MK (1985) Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity. J Clin Endocrinol Metab 60:1093–1096PubMedGoogle Scholar
  107. 107.
    Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E (2004) Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579–581PubMedGoogle Scholar
  108. 108.
    Garringer HJ, Fisher C, Larsson TE, Davis SI, Koller DL, Cullen MJ, Draman MS, Conlon N, Jain A, Fedarko NS, Dasgupta B, White KE (2006) The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 91:4037–4042PubMedGoogle Scholar
  109. 109.
    Kato K, Jeanneau C, Tarp MA, Benet-Pages A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Clausen H (2006) Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281:18370–18377PubMedGoogle Scholar
  110. 110.
    Ichikawa S, Lyles KW, Econs MJ (2005) A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab 90:2420–2423PubMedGoogle Scholar
  111. 111.
    Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T (2005) A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90:5523–5527PubMedGoogle Scholar
  112. 112.
    Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE (2005) A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424–2427PubMedGoogle Scholar
  113. 113.
    Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B (2005) An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385–390PubMedGoogle Scholar
  114. 114.
    Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561–568PubMedGoogle Scholar
  115. 115.
    Brownstein CA, Adler F, Nelson-Williams C, Iijima J, Li P, Imura A, Nabeshima Y, Reyes-Mugica M, Carpenter TO, Lifton RP (2008) A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 105:3455–3460PubMedGoogle Scholar
  116. 116.
    Antoniucci DM, Yamashita T, Portale AA (2006) Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91:3144–3149PubMedGoogle Scholar
  117. 117.
    Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205–2215PubMedGoogle Scholar
  118. 118.
    Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y (2004) FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65:1943–1946PubMedGoogle Scholar
  119. 119.
    Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592PubMedGoogle Scholar
  120. 120.
    Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M (2005) Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67:1171–1178PubMedGoogle Scholar

Copyright information

© IPNA 2009

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of Texas Southwestern Medical Center at DallasDallasUSA
  2. 2.Department of Internal MedicineUniversity of Texas Southwestern Medical Center at DallasDallasUSA

Personalised recommendations